Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $27.84 Consensus Price Target from Brokerages

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have earned an average rating of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating. The average 1 year target price among analysts that have covered the stock in the last year is $27.84.

Separately, StockNews.com assumed coverage on Cara Therapeutics in a report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Cara Therapeutics Stock Up 0.4 %

NASDAQ CARA opened at $5.01 on Friday. Cara Therapeutics has a twelve month low of $2.71 and a twelve month high of $13.80. The business has a 50-day moving average price of $4.39 and a 200-day moving average price of $3.98. The firm has a market cap of $22.90 million, a price-to-earnings ratio of -0.24 and a beta of 0.51.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CARA. Disciplined Growth Investors Inc. MN boosted its position in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares during the period. XTX Topco Ltd bought a new stake in shares of Cara Therapeutics during the 3rd quarter worth approximately $29,000. Finally, FMR LLC boosted its holdings in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the period. Institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.